1198088-67-3

Basic information

• Product Name: 6-(3,4-dimethoxyphenyl)-4-(3,4-methylenedioxyphenyl)-1H-pyridin-2-one
• Synonyms: 6-(3,4-dimethoxyphenyl)-4-(3,4-methylenedioxyphenyl)-1H-pyridin-2-one
• CAS NO: 1198088-67-3
• Molecular Weight: 351.359
• Mol File: 1198088-67-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 6-(3,4-dimethoxyphenyl)-4-(3,4-methylenedioxyphenyl)-1H-pyridin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(3,4-dimethoxyphenyl)-4-(3,4-methylenedioxyphenyl)-1H-pyridin-2-one(1198088-67-3)
• EPA Substance Registry System: 6-(3,4-dimethoxyphenyl)-4-(3,4-methylenedioxyphenyl)-1H-pyridin-2-one(1198088-67-3)

Safety Data

• Hazardous Substances Data: 1198088-67-3(Hazardous Substances Data)

Upstream product

• 120-57-0 piperonal 
• 1131-62-0 1-(3,4-dimethoxyphenyl)ethanone 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 2620-63-5 2-acetamidoacetamide 
• 51116-22-4 3‐(benzo[d][1,3]dioxol‐5‐yl)‐1‐(3,4‐dimethoxyphenyl)prop‐2‐en‐1‐one 

Relevant articles and documents

The synthesis of 4,6-diaryl-2-pyridones and their bioactivation in CYP1 expressing breast cancer cells

As part of a programme to develop anticancer prodrugs which are activated by cytochrome P450 (CYP)1B1, a library of 4,6-diaryl-2-pyridones was synthesised in yields of 6–60% from the corresponding chalcones. A number of these derivatives showed promising antiproliferative activities in human breast cancer cell lines which express CYP1B1 and CYP1A1, while showing little toxicity towards a non-tumour breast cell line with no CYP expression. Metabolism studies provided evidence supporting the involvement of CYP1 enzymes in the bioactivation of these compounds.

4, 6-DIPHENYLPYRID-2-0NES AGAINST CANCER

A compound for use in the treatment of proliferative disorders, such as cancer, having the following formula:z wherein: R1, R2 and R3 are independently H or lower alkyl; R4, R5, R6, R7 and R8 are independently H, halo, lower alkyl or -O-lower alkyl, provided that at least one is -O-lower alkyl; or at least one pair of R4 to R8, the members of which pair are adjacent to one another on the ring, are conjoined to form-0-(CR14R15)n-O-, where n is 1 or 2 and R14 and R15 are independently H or lower alkyl, and the remainder of R4 to R8 are independently H, halo, lower alkyl or -O-lower alkyl; and R9, R10, R11, R12 and R13 are independently H, halo, lower alkyl or -O-lower alkyl, provided that at least one is -O-lower alkyl; or at least one pair of R9 to R13, the members of which pair are adjacent to one another on the ring, are conjoined to form-O-(CR16R17)m-O-, where m is 1 or 2 and R16 and R17 are independently H or lower alkyl, and the remainder of R9 to R13 are independently H, halo, lower alkyl or -O-lower alkyl.